Belite Bio Inc Adr (BLTE)

May 05, 2026

Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares - Investing.com

May 05, 2026

May 05, 2026

Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS - Stock Titan

May 05, 2026

May 04, 2026

Belite Bio CSO Nathan Mata sells $155,777 in shares By Investing.com - Investing.com South Africa

May 04, 2026

May 04, 2026

Belite Bio (BLTE) CSO pre-planned sale of 1,000 ADS around $160 - Stock Titan

May 04, 2026

May 01, 2026

Belite Bio (BLTE) CSO sells 1,000 ADS in planned trades - Stock Titan

May 01, 2026

May 01, 2026

Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - Yahoo Finance

May 01, 2026

May 01, 2026

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

May 01, 2026

Apr 30, 2026

Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus - Barchart

Apr 30, 2026

Apr 30, 2026

Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares - MarketBeat

Apr 30, 2026

Apr 30, 2026

(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily

Apr 30, 2026

Apr 30, 2026

Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under 10b5-1 plan - Stock Titan

Apr 30, 2026

Apr 29, 2026

Belite bio CSO Nathan Mata sells $159,162 in shares - Investing.com

Apr 29, 2026

Apr 29, 2026

Belite bio CSO Nathan Mata sells $159,162 in shares By Investing.com - Investing.com India

Apr 29, 2026

Apr 29, 2026

Belite Bio (BLTE) CSO sells 1,000 ADS in planned open-market trades - Stock Titan

Apr 29, 2026

Apr 28, 2026

A Look At Belite Bio (BLTE) Valuation As Tinlarebant NDA Submission Progresses - Sahm

Apr 28, 2026

Apr 28, 2026

Belite Bio (NASDAQ:BLTE) Insider Sells $162,640.00 in Stock - MarketBeat

Apr 28, 2026

Apr 28, 2026

Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares - Investing.com India

Apr 28, 2026

Apr 28, 2026

Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares By Investing.com - Investing.com South Africa

Apr 28, 2026

Apr 28, 2026

Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan

Apr 28, 2026

Apr 28, 2026

Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor ConferenceSlideshow - Seeking Alpha

Apr 28, 2026

Apr 28, 2026

Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference - MarketBeat

Apr 28, 2026

Apr 28, 2026

Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, Apr-28-2026 09 - marketscreener.com

Apr 28, 2026

Apr 27, 2026

Belite Bio (NASDAQ:BLTE) Insider Sells $159,560.00 in Stock - MarketBeat

Apr 27, 2026

Apr 27, 2026

Belite Bio chief scientific officer Nathan Mata sells $159,555 in stock - Investing.com India

Apr 27, 2026

Apr 27, 2026

Belite Bio (BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan

Apr 27, 2026

Apr 27, 2026

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit - The Manila Times

Apr 27, 2026

Apr 24, 2026

Belite Bio CSO Nathan Mata sells $166,283 in shares By Investing.com - Investing.com Australia

Apr 24, 2026

Apr 24, 2026

Belite Bio CSO Nathan Mata sells $166,283 in shares - Investing.com

Apr 24, 2026

Apr 24, 2026

Belite Bio (BLTE) CSO sells 1,000 ADS in Rule 10b5-1 trades - Stock Titan

Apr 24, 2026

Apr 23, 2026

Belite Bio CSO Nathan Mata sells $170,384 in shares By Investing.com - Investing.com South Africa

Apr 23, 2026

Apr 23, 2026

Belite Bio CSO Nathan Mata sells $170,384 in shares - Investing.com

Apr 23, 2026

Apr 23, 2026

BELITE BIO (BLTE) CEO gains 10,000 shares from vested RSUs - Stock Titan

Apr 23, 2026

Apr 23, 2026

[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan

Apr 23, 2026

Apr 23, 2026

Belite Bio (BLTE) CFO RSUs vest into 10,000 ordinary shares - Stock Titan

Apr 23, 2026

Apr 23, 2026

Belite Bio to Participate in Four Upcoming Investor Conferences - markets.businessinsider.com

Apr 23, 2026

Apr 23, 2026

Four Belite Bio conference appearances are set from April 28 to May 26 - Stock Titan

Apr 23, 2026

Apr 22, 2026

Belite Bio chief scientific officer sells $166,000 in shares By Investing.com - Investing.com Canada

Apr 22, 2026

Apr 22, 2026

Belite Bio chief scientific officer sells $166,000 in shares - Investing.com

Apr 22, 2026

Apr 22, 2026

Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS disclosed - Stock Titan

Apr 22, 2026

Apr 22, 2026

Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks - TipRanks

Apr 22, 2026

Apr 22, 2026

Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th - marketscreener.com

Apr 22, 2026

Apr 22, 2026

Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - MarketBeat

Apr 22, 2026

Apr 22, 2026

Belite Bio begins rolling NDA submission for Stargardt treatment By Investing.com - Investing.com India

Apr 22, 2026

Apr 21, 2026

Belite Bio CSO Nathan Mata sells $163,594 in shares By Investing.com - Investing.com Canada

Apr 21, 2026

Apr 21, 2026

Belite Bio CSO Nathan Mata sells $163,594 in shares - Investing.com

Apr 21, 2026

Apr 21, 2026

Belite Bio begins rolling NDA submission for Stargardt treatment - Investing.com

Apr 21, 2026

Apr 21, 2026

Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease - TipRanks

Apr 21, 2026